Hsp70-p53合成肽修饰树突状细胞诱导细胞免疫应答的研究
详细信息 查看官网全文
- 英文论文题名：The cellular Immune response Induced by Hsp70-p53 peptide complex-modified Dendritic cells
- 论文作者：刘伟 ; 施宇光 ; 金茜 ; 赵冬梅 ; 李兴库 ; 刘伟
- 英文论文作者：Lin Wei ; SHi Yu-guang ; Jin Qian ; Zhao Dong-mei ; Liu Wei
- 年：2016
- 作者机构：哈尔滨医科大学心肌缺血省部共建重点实验室;哈尔滨医科大学附属第二医院科研实验中心;
- 论文关键词：树突状细胞 ; 热休克蛋白-p53合成肽复合物 ; 修饰 ; 抗瘤免疫
- 英文论文关键词：DC ; Hsp70-p53 peptide complex ; Modification ; Antitumor-immunity
- 会议召开时间：2016年6月
- 会议录名称：2016《中国组织化学与细胞化学》杂志临床研究研讨会论文汇编
- 语种：中文
- 分类号：R392
- 学会代码：ZHXB
- 会议名称：2016《中国组织化学与细胞化学》杂志临床研究研讨会
- 会议地点：中国北京
- 主办单位：《中国组织化学与细胞化学杂志》社有限公司
- 学会名称：《中国组织化学与细胞化学杂志》社有限公司
- 页数：2
- 文件大小：621k
- 原文格式：O
- 会议级别：全国
摘要
目的:研究Hsp70-p53合成肽复合物修饰的树突状细胞(DC)诱导的细胞免疫应答。方法:人工合成p53蛋白多肽,在体外与热休克蛋白Hsp70结合形成Hsp70-p53合成肽复合物后,修饰DC,以肿瘤细胞抗原肽作对照,刺激健康人外周血T淋巴细胞。检测增殖活化的T细胞对肿瘤细胞的杀伤功能及细胞因子表达水平。结果:Hsp70-p53合成肽复合物可促进DC成熟,分泌大量IL-12等细胞因子;并可刺激异体T淋巴细胞增殖,与单纯DC组比较有极显著差异(P<0.01);修饰的DC活化T细胞与单纯肿瘤抗原肽组对BEL-7402肝癌细胞杀伤作用无显著差异(P>0.05),而对7901胃癌细胞有差异(P<0.05)。结论:Hsp70-p53合成肽复合物能够修饰DC使其活化,激活T淋巴细胞,对高效表达突变型p53蛋白的肿瘤细胞株产生有效的杀伤作用。
Objective:To study the cellular immune response induced by Hsp70- p53 synthesized peptide complex- modified dendritic cells(DC).Methods:The p53_(W) as synthesized and bound Hsp70 in vitro:with DCs modified by Hsp70- p53 peptide or tumor antigen peptides.The proportion of stimulated T cells and The cytolytic effect of those activated T cells on cancer cells was tested.The expression oi cytokines in the T cells were examined.Results:The DCs could be activated and expressed large amount of IL- 12 by Hsp70- p53 peptide complex,there was significant difference between Hsp70- p53 and tumor antigen(P <0.01).T cell could be stimulated and proliferated by Hsp70- p53- modified DCs.There was significant difference between T cells stimulated with DCs and Hsp70- p53- modified DCs(P < 0.01).There was no significant difference between cytolytic effects of T cells activated with Hsp70- p53- modified DCs and tumor antigen- treated DCs(P >0.05) on BEL-7402 cells,while there was significant difference between that with Hsp70- p53- modified DCs and tumor antigen-treated DCs(P<0.05) on 7901 cells.Conclusion:DCs could be modified effectively by Hsp- p53 synthesized peptide-complexes.The modified DCs could activated specific T lymphocytes in vitro.
Objective:To study the cellular immune response induced by Hsp70- p53 synthesized peptide complex- modified dendritic cells(DC).Methods:The p53_(W) as synthesized and bound Hsp70 in vitro:with DCs modified by Hsp70- p53 peptide or tumor antigen peptides.The proportion of stimulated T cells and The cytolytic effect of those activated T cells on cancer cells was tested.The expression oi cytokines in the T cells were examined.Results:The DCs could be activated and expressed large amount of IL- 12 by Hsp70- p53 peptide complex,there was significant difference between Hsp70- p53 and tumor antigen(P <0.01).T cell could be stimulated and proliferated by Hsp70- p53- modified DCs.There was significant difference between T cells stimulated with DCs and Hsp70- p53- modified DCs(P < 0.01).There was no significant difference between cytolytic effects of T cells activated with Hsp70- p53- modified DCs and tumor antigen- treated DCs(P >0.05) on BEL-7402 cells,while there was significant difference between that with Hsp70- p53- modified DCs and tumor antigen-treated DCs(P<0.05) on 7901 cells.Conclusion:DCs could be modified effectively by Hsp- p53 synthesized peptide-complexes.The modified DCs could activated specific T lymphocytes in vitro.
引文
[1]Seiter S,Marincola FM,The multipe ways to tumor tolerance.Mod Asp Immunoboil,2000 1(3):121.
[2]Blachere NE,Udono H,Janetzki S,et al.Heat shock protein vaccines against cancer.J Immunother Emphasis Tumor Immunol 1993,11;14(4):352-6.
[3]Schuler PJ1,Harasymczuk M,Visus C,et al.Phase I dendritic cell p53peptide vaccine for head and neck cancer.Clin Cancer Res,2014,5,20(9):2433-44.
[4]施宇光等,刘伟.Survivin HLA—A2+高亲和性CTL表位合成肽修饰的树突状细胞免疫功能的体外实验研究.实用医学杂志,2015,7:19—21.
[5]Tamura Y,Peng P,Liu K,et al.Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations[J].Science,1997,278(5335):117.
[6]Arnold-Schild D,Hanau D,Spehner D,et al.Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells.J Immunol,1999,162:3757-3760.
[7]Castellino F,Boucher PE,Eichelberg K,et al.Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways.J Exp Med,2000,191:1957-1964.
[2]Blachere NE,Udono H,Janetzki S,et al.Heat shock protein vaccines against cancer.J Immunother Emphasis Tumor Immunol 1993,11;14(4):352-6.
[3]Schuler PJ1,Harasymczuk M,Visus C,et al.Phase I dendritic cell p53peptide vaccine for head and neck cancer.Clin Cancer Res,2014,5,20(9):2433-44.
[4]施宇光等,刘伟.Survivin HLA—A2+高亲和性CTL表位合成肽修饰的树突状细胞免疫功能的体外实验研究.实用医学杂志,2015,7:19—21.
[5]Tamura Y,Peng P,Liu K,et al.Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations[J].Science,1997,278(5335):117.
[6]Arnold-Schild D,Hanau D,Spehner D,et al.Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells.J Immunol,1999,162:3757-3760.
[7]Castellino F,Boucher PE,Eichelberg K,et al.Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways.J Exp Med,2000,191:1957-1964.